Showing 1 - 10 of 128
There are three analytically distinct layers of the phenomenon that has been labeled 'the anticommons' and indicted as a potential impediment to innovation resulting from patenting and enforcement of IPR obtained on academic research results. This paper distinguishes among 'search costs',...
Persistent link: https://www.econbiz.de/10008784446
This paper examines the impact of the R&D fiscal incentive program on R&D by Dutch firms. Taking a factor-demand approach we measure the elasticity of firm R&D capital accumulation to its user cost. Econometric models are estimated using a rich unbalanced panel of firm data covering the period...
Persistent link: https://www.econbiz.de/10008642572
While in 1996, 12 OECD countries offered R&D tax incentives, in 2008 this number increased to 21. Most countries have opted for level-based instead of incremental R&D tax incentives. This paper takes a critical look at how the effectiveness of R&D tax incentives has been assessed in recent...
Persistent link: https://www.econbiz.de/10005256453
In this paper we evaluate the effectiveness of R&D tax incentives in Quebec, using manufacturing firm data from 1997 to 2003 originating from R&D surveys, annual surveys of manufactures and administrative data. The estimated price elasticity of R&D is -0.10 in the short run and -0.14 in the long...
Persistent link: https://www.econbiz.de/10005150861
This paper examines the impact of the Dutch R&D fiscal incentive program, known as WBSO, on R&D capital formation. Taking a factor-demand approach we measure the elasticity of firm R&D capital accumulation to its user cost. An econometric model is estimated using a rich unbalanced panel covering...
Persistent link: https://www.econbiz.de/10005150873
The Indian pharmaceutical industry is presently going through a phase of transition and potential consolidation, owing to India's new TRIPS-compliant intellectual property regime and other rules aimed at enhancing the industry's credibility nationally and internationally. Appropriate policy...
Persistent link: https://www.econbiz.de/10005150874
We take a first look at financial patents at the European Patent Office (EPO). As is the case at the US Patent and … firms in non-financial sectors with diversified patent portfolios own a large share of financial patents at the EPO. However … patent applications take longer and they are more likely to be refused by the patent office, suggesting greater uncertainty …
Persistent link: https://www.econbiz.de/10008615254
When companies decide to engage in technology transfer through licensing to other firms, they have two basic options: to use standard licensing contracts or to set-up more elaborate partnership-embedded licensing agreements. We find that broader partnership-embedded licensing agreements are...
Persistent link: https://www.econbiz.de/10005451581
The impact of patent protection on biomedical innovation has been a controversial issue. Although a "medical anti … develops a framework of analysis for the impact of patent rights on biomedical innovation in "technology follower" developing … pharmaceutical industry between November 2004 and January 2005 is used to analyze the impact of patent rights as recognized under the …
Persistent link: https://www.econbiz.de/10005150790
The year 2005 marks the end of transition period for many developing countries with competent pharmaceutical sectors that competed in supplying generic versions of patented drugs to LDCs before, thereby inducing price competition and enhancing access to medicines. In a post-2005 scenario, the...
Persistent link: https://www.econbiz.de/10005150801